Cited by 1,059Lung Cancer Treatments and MutationsHER2/EGFR in Cancer ResearchCancer Genomics and Diagnostics

The DOI matches its Crossref record; 37 of the 37 references it cites were found in a registry or an index.

Preexistence and Clonal Selection of MET Amplification in EGFR Mutant NSCLC

Open access

Turke, Alexa B., Zejnullahu, Kreshnik, Wu, Yi-Long, Song, Youngchul, Dias-Santagata, Dora, Lifshits, Eugene, Toschi, Luca, Rogers, Andrew, Mok, Tony, Sequist, Lecia, Lindeman, Neal I., Murphy, Carly, Akhavanfard, Sara, Yeap, Beow Y., Xiao, Yun, Capelletti, Marzia, Iafrate, A. John, Lee, Charles, Christensen, James G., Engelman, Jeffrey A., Jänne, Pasi A.·2010·Cancer Cell

DOI 10.1016/j.ccr.2009.11.022PMC PMC2980857

Open this paper in CoChat — free account Open PDF

Abstract

MET amplification activates ERBB3/PI3K/AKT signaling in EGFR mutant lung cancers and causes resistance to EGFR kinase inhibitors. We demonstrate that MET activation by its ligand, HGF, also induces drug resistance, but through GAB1 signaling. Using high-throughput FISH analyses in both cell lines and in patients with lung cancer, we identify subpopulations of cells with MET amplification prior to drug exposure. Surprisingly, HGF accelerates the development of MET amplification both in vitro and in vivo. EGFR kinase inhibitor resistance, due to either MET amplification or autocrine HGF production, was cured in vivo by combined EGFR and MET inhibition. These findings highlight the potential to prospectively identify treatment naive, patients with EGFR-mutant lung cancer who will benefit from initial combination therapy.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1016/j.ccr.2009.11.022

Cites

37 of 37 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Gefitinib or Carboplatin–Paclitaxel in Pulmonary Adenocarcinoma
Mok, T. S., Wu, Y.-L., Thongprasert, S., Yang, C.-H., Chu, D.-T., Saijo, N., Sunpaweravong, P., Han, B., Margono, B., Ichinose, Y., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0810699 · Cited by 8,261
Self-citation
MET Amplification Leads to Gefitinib Resistance in Lung Cancer by Activating ERBB3 Signaling
Engelman, J. A., Zejnullahu, K., Mitsudomi, T., Song, Y., Hyland, C., Park, J. O., Lindeman, N., Gale, C.-M., Zhao, X., Christensen, J., et al. (2007) · Science · doi:10.1126/science.1141478 · Cited by 4,496
Self-citation
Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors
Demetri, G. D., von Mehren, M., Blanke, C. D., Van den Abbeele, A. D., Eisenberg, B., Roberts, P. J., Heinrich, M. C., Tuveson, D. A., Singer, S., Janicek, M., et al. (2002) · New England Journal of Medicine · doi:10.1056/nejmoa020461 · Cited by 4,389
EGFR Mutation and Resistance of Non–Small-Cell Lung Cancer to Gefitinib
Kobayashi, S., Boggon, T. J., Dayaram, T., Jänne, P. A., Kocher, O., Meyerson, M., Johnson, B. E., Eck, M. J., Tenen, D. G., & Halmos, B. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa044238 · Cited by 3,964
Acquired Resistance of Lung Adenocarcinomas to Gefitinib or Erlotinib Is Associated with a Second Mutation in the EGFR Kinase Domain
Pao, W., Miller, V. A., Politi, K. A., Riely, G. J., Somwar, R., Zakowski, M. F., Kris, M. G., & Varmus, H. (2005) · PLoS Medicine · doi:10.1371/journal.pmed.0020073 · Cited by 3,527 · cited 2×
“Secondary mutations in EGFR itself, including the EGFR T790M ‘‘gatekeeper’’ mutation is observed in 50% of resistance cases, and amplification of the MET oncogene is observed in 20% of resistance cases (Balak et al., 2006; Bean et al., 2007; Engelman et al., 2007b; Kobayashi et al., 2005; Kosaka et al., 2006; Pao et a…”
Background
Clinical Resistance to STI-571 Cancer Therapy Caused by BCR-ABL Gene Mutation or Amplification
Gorre, M. E., Mohammed, M., Ellwood, K., Hsu, N., Paquette, R., Rao, P. N., & Sawyers, C. L. (2001) · Science · doi:10.1126/science.1062538 · Cited by 3,104
Activity of a Specific Inhibitor of the BCR-ABL Tyrosine Kinase in the Blast Crisis of Chronic Myeloid Leukemia and Acute Lymphoblastic Leukemia with the Philadelphia Chromosome
Druker, B. J., Sawyers, C. L., Kantarjian, H., Resta, D. J., Reese, S. F., Ford, J. M., Capdeville, R., & Talpaz, M. (2001) · New England Journal of Medicine · doi:10.1056/nejm200104053441402 · Cited by 2,713
Screening for Epidermal Growth Factor Receptor Mutations in Lung Cancer
Rosell, R., Moran, T., Queralt, C., Porta, R., Cardenal, F., Camps, C., Majem, M., Lopez-Vivanco, G., Isla, D., Provencio, M., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0904554 · Cited by 2,373
The T790M mutation in EGFR kinase causes drug resistance by increasing the affinity for ATP
Yun, C.-H., Mengwasser, K. E., Toms, A. V., Woo, M. S., Greulich, H., Wong, K.-K., Meyerson, M., & Eck, M. J. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0709662105 · Cited by 2,118 · cited 2×
“To date, resistance mechanisms have predominately involved secondary genomic alterations in the target kinase that alter either the physical (such as steric hindrance) or biochemical (change in ATP affinity) properties of the receptor and result in drug resistance (Gorre et al., 2001; Shah et al., 2002; Yun et al., 20…”
Background
Detection of Mutations in EGFR in Circulating Lung-Cancer Cells
Maheswaran, S., Sequist, L. V., Nagrath, S., Ulkus, L., Brannigan, B., Collura, C. V., Inserra, E., Diederichs, S., Iafrate, A. J., Bell, D. W., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0800668 · Cited by 1,617
Self-citation

Show all 37 references

Sorted by citations

Items 301–400 of 1,000

The Met oncogene and basal-like breast cancer: another culprit to watch out for?
Gastaldi, S., Comoglio, P. M., & Trusolino, L. (2010) · Breast Cancer Research · doi:10.1186/bcr2617 · Cited by 78
Primary human cervical carcinoma cells require human papillomavirus E6 and E7 expression for ongoing proliferation
Magaldi, T. G., Almstead, L. L., Bellone, S., Prevatt, E. G., Santin, A. D., & DiMaio, D. (2011) · Virology · doi:10.1016/j.virol.2011.10.012 · Cited by 73
Targeting C4-Demethylating Genes in the Cholesterol Pathway Sensitizes Cancer Cells to EGF Receptor Inhibitors via Increased EGF Receptor Degradation
Sukhanova, A. L., Gorin, A. A., Serebriiskii, I. G., Gabitova, L., Zheng, H., Restifo, D., Egleston, B. L., Cunningham, D., Bagnyukova, T., Liu, H., et al. (2012) · Cancer Discovery · doi:10.1158/2159-8290.cd-12-0031 · Cited by 77
Synergistic Effects of Foretinib with HER-Targeted Agents in MET and HER1- or HER2-Coactivated Tumor Cells
Liu, L., Shi, H., Liu, Y., Anderson, A. E., Peterson, J. J., Greger, J., Martin, A., & Gilmer, T. M. (2011) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-10-0698 · Cited by 74
Breast cancer intratumor genetic heterogeneity: causes and implications
Ng, C. K. Y., Pemberton, H. N., & Reis-Filho, J. S. (2012) · Expert Review of Anticancer Therapy · doi:10.1586/era.12.85 · Cited by 77
MEK inhibitors reverse resistance in epidermal growth factor receptor mutation lung cancer cells with acquired resistance to gefitinib
Huang, M.-H., Lee, J., Chang, Y., Tsai, H.-H., Lin, Y., Lin, A. M.-Y., & Yang, J. C. (2012) · Molecular Oncology · doi:10.1016/j.molonc.2012.09.002 · Cited by 74
TAK-701, a Humanized Monoclonal Antibody to Hepatocyte Growth Factor, Reverses Gefitinib Resistance Induced by Tumor-Derived HGF in Non–Small Cell Lung Cancer with an EGFR Mutation
Okamoto, W., Okamoto, I., Tanaka, K., Hatashita, E., Yamada, Y., Kuwata, K., Yamaguchi, H., Arao, T., Nishio, K., Fukuoka, M., et al. (2010) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-10-0481 · Cited by 74
Blockade of Hedgehog Signaling Synergistically Increases Sensitivity to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Non-Small-Cell Lung Cancer Cell Lines
Bai, X., Zhang, X., Yang, S., An, S., Chen, Z., Su, J., Xie, Z., Gou, L.-Y., & Wu, Y.-L. L. C. (2016) · PLoS ONE · doi:10.1371/journal.pone.0149370 · Cited by 72
Self-citation
Advances on EGFR mutation for lung cancer.
Metro, G., & Crinò, L. (2012) · Europe PMC (PubMed Central) · doi:10.3978/j.issn.2218-6751.2011.12.01 · Cited by 73
Biomarkers in Lung Adenocarcinoma: A Decade of Progress
Sholl, L. M. (2014) · Archives of Pathology & Laboratory Medicine · doi:10.5858/arpa.2014-0128-ra · Cited by 75
MET/HGF pathway activation as a paradigm of resistance to targeted therapies
Ko, B., He, T., Gadgeel, S. M., & Halmos, B. (2017) · Annals of Translational Medicine · doi:10.21037/atm.2016.12.09 · Cited by 71
Targeting EGFR in non-small-cell lung cancer: Lessons, experiences, strategies
Stella, G. M., Luisetti, M., Inghilleri, S., Cemmi, F., Scabini, R., Zorzetto, M., & Pozzi, E. (2011) · Respiratory Medicine · doi:10.1016/j.rmed.2011.10.015 · Cited by 73
Thirty Years of Research on Met Receptor to Move a Biomarker from Bench to Bedside
Furlan, A., Kherrouche, Z., Montagne, R., Copin, M., & Tulasne, D. (2014) · Cancer Research · doi:10.1158/0008-5472.can-14-1932 · Cited by 70
Aromatase inhibition remodels the clonal architecture of estrogen-receptor-positive breast cancers
Miller, C. A., Gindin, Y., Lu, C., Griffith, O. L., Griffith, M., Shen, D., Hoog, J., Li, T., Larson, D. E., Watson, M. A., et al. (2016) · Nature Communications · doi:10.1038/ncomms12498 · Cited by 69
Heterogeneity in Melanoma
Shannan, B., Perego, M., Somasundaram, R., & Herlyn, M. (2015) · Cancer treatment and research · doi:10.1007/978-3-319-22539-5_1 · Cited by 70
Combined inhibition of MEK and PI3K pathways overcomes acquired resistance to EGFR‐TKIs in non‐small cell lung cancer
Sato, H., Yamamoto, H., Sakaguchi, M., Shien, K., Tomida, S., Shien, T., Ikeda, H., Hatono, M., Torigoe, H., Namba, K., et al. (2018) · Cancer Science · doi:10.1111/cas.13763 · Cited by 72
Driver network as a biomarker: systematic integration and network modeling of multi-omics data to derive driver signaling pathways for drug combination prediction
Huang, L. F., Brunell, D. J., STEPHAN, C. C., Mancuso, J. J., Yu, X., He, B., Thompson, T. C., Zinner, R., Kim, J., Davies, P. J., et al. (2019) · Bioinformatics · doi:10.1093/bioinformatics/btz109 · Cited by 72
Molecular oncology of lung cancer
Toyooka, S., Mitsudomi, T., Soh, J., Aokage, K., Yamane, M., Oto, T., Kiura, K., & Miyoshi, S. (2011) · General Thoracic and Cardiovascular Surgery · doi:10.1007/s11748-010-0743-3 · Cited by 69
Genetic Mutations and Epigenetic Modifications: Driving Cancer and Informing Precision Medicine
Coyle, K. M., Boudreau, J. E., & Marcato, P. (2017) · BioMed Research International · doi:10.1155/2017/9620870 · Cited by 72
The ethical use of mandatory research biopsies
Olson, E. M., Lin, N., Krop, I. E., & Winer, E. P. (2011) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2011.114 · Cited by 68
Ligand‐triggered resistance to molecular targeted drugs in lung cancer: Roles of hepatocyte growth factor and epidermal growth factor receptor ligands
Yano, S., Takeuchi, S., Nakagawa, T., & Yamada, T. (2012) · Cancer Science · doi:10.1111/j.1349-7006.2012.02279.x · Cited by 68
High-SensitivityBRAFMutation Analysis:BRAFV600E Is Acquired Early During Tumor Development but Is Heterogeneously Distributed in a Subset of Papillary Thyroid Carcinomas
de Biase, D., Cesari, V., Visani, M., Casadei, G. P., Cremonini, N., Gandolfi, G., Sancisi, V., Ragazzi, M., Pession, A., Ciarrocchi, A., et al. (2014) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2013-4389 · Cited by 68
Inhibition of Tumor Growth and Metastasis in Non–Small Cell Lung Cancer by LY2801653, an Inhibitor of Several Oncokinases, Including MET
Wu, W., Chen, B., Credille, K. M., Manro, J. R., Peek, V. L., Donoho, G. P., Yan, L., Wijsman, J. A., Yan, S.-C. B., & Walgren, R. A. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-1758 · Cited by 68
Oncogenic drivers, targeted therapies, and acquired resistance in non-small-cell lung cancer
Gower, A., Wang, Y., & Giaccone, G. (2014) · Journal of Molecular Medicine · doi:10.1007/s00109-014-1165-y · Cited by 68
Co-existence of positive MET FISH status with EGFR mutations signifies poor prognosis in lung adenocarcinoma patients
Tanaka, A., Sueoka‐Aragane, N., Nakamura, T., Takeda, Y., Mitsuoka, M., Yamasaki, F., Hayashi, S., Sueoka, E., & Kimura, S. H. (2011) · Lung Cancer · doi:10.1016/j.lungcan.2011.06.004 · Cited by 67
Recent advances in gold and silver nanoparticle based therapies for lung and breast cancers
Malik, P., & Mukherjee, T. K. (2018) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2018.10.048 · Cited by 70
Overcoming drug resistance to receptor tyrosine kinase inhibitors: Learning from lung cancer
Kuwano, M., Sonoda, K., Murakami, Y., Watari, K., & Ono, M. (2016) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2016.03.002 · Cited by 66
MET targeting: time for a rematch
Koch, J. P., Aebersold, D. M., Zimmer, Y., & Medová, M. (2020) · Oncogene · doi:10.1038/s41388-020-1193-8 · Cited by 66
Receptor Tyrosine Kinases Fall into Distinct Classes Based on Their Inferred Signaling Networks
Wagner, J. P., Wolf‐Yadlin, A., Sevecka, M., Grenier, J. K., Root, D. E., Lauffenburger, D. A., & MacBeath, G. (2013) · Science Signaling · doi:10.1126/scisignal.2003994 · Cited by 68
What’s new in non-small cell lung cancer for pathologists the importance of accurate subtyping, EGFR mutations and ALK rearrangements
Cooper, W. A., O'Toole, S. A., Boyer, M. J., Horvath, L. G., & Mahar, A. M. (2011) · Pathology · doi:10.1097/pat.0b013e328342629d · Cited by 67
The MET Oncogene in Glioblastoma Stem Cells: Implications as a Diagnostic Marker and a Therapeutic Target
Boccaccio, C., & Comoglio, P. M. (2013) · Cancer Research · doi:10.1158/0008-5472.can-12-4039 · Cited by 66
Towards patient-based cancer therapeutics
The Cancer Target Discovery and Development Network, Schreiber, S. L., Shamji, A. F., Clemons, P. A., Hon, C., Koehler, A. N., Muñoz, B., Palmer, M. A. J., Stern, A. M., Wagner, B. K., et al. (2010) · Nature Biotechnology · doi:10.1038/nbt0910-904 · Cited by 66
The resistance mechanisms and treatment strategies for EGFR -mutant advanced non-small-cell lung cancer
Zhong, W., Zhou, Q. H., & Wu, Y.-L. L. C. (2017) · Oncotarget · doi:10.18632/oncotarget.20311 · Cited by 66
Self-citation
Dual Inhibition of Met Kinase and Angiogenesis to Overcome HGF-Induced EGFR-TKI Resistance in EGFR Mutant Lung Cancer
Takeuchi, S., Wang, W., Li, Q., Yamada, T., Kita, K., Donev, I. S., Nakamura, T., Matsumoto, K., Shimizu, E., Nishioka, Y., et al. (2012) · American Journal Of Pathology · doi:10.1016/j.ajpath.2012.05.023 · Cited by 68
The RAF-MEK-ERK Pathway: Targeting ERK to Overcome Obstacles of Effective Cancer Therapy
Yu, Z., Ye, S., Hu, G., Lv, M., Tu, Z., Zhou, K., & Li, Q. (2015) · Future Medicinal Chemistry · doi:10.4155/fmc.14.143 · Cited by 66
Adaptive informatics for multifactorial and high-content biological data
Millard, B. L., Niepel, M., Menden, M. P., Muhlich, J. L., & Sorger, P. K. (2011) · Nature Methods · doi:10.1038/nmeth.1600 · Cited by 65
Mechanisms of resistance to EGFR targeted therapies
Hrustanovic, G., Lee, B. J., & Bivona, T. G. (2013) · Cancer Biology & Therapy · doi:10.4161/cbt.23627 · Cited by 67
Clonal cooperativity in heterogenous cancers
Zhou, H., Neelakantan, D., & Ford, H. L. (2016) · Seminars in Cell and Developmental Biology · doi:10.1016/j.semcdb.2016.08.028 · Cited by 66
From targets to targeted therapies and molecular profiling in non-small cell lung carcinoma
Thomas, A., Rajan, A., López-Chávez, A., Wang, Y., & Giaccone, G. (2012) · Annals of Oncology · doi:10.1093/annonc/mds478 · Cited by 63
Silencing of Receptor Tyrosine Kinase ROR1 Inhibits Tumor-Cell Proliferation via PI3K/AKT/mTOR Signaling Pathway in Lung Adenocarcinoma
Liu, Y., Yang, H., Chen, T., Luo, Y., Xu, Z., Li, Y., & Yang, J. (2015) · PLoS ONE · doi:10.1371/journal.pone.0127092 · Cited by 66
Genetic Evolution of Glioblastoma Stem-Like Cells From Primary to Recurrent Tumor
Orzan, F., Bacco, F. D., Crisafulli, G., Pellegatta, S., Mussolin, B., Siravegna, G., D’Ambrosio, A., Comoglio, P. M., Finocchiaro, G., & Boccaccio, C. (2017) · Stem Cells · doi:10.1002/stem.2703 · Cited by 63
Resistance to EGFR inhibitors in non-small cell lung cancer: Clinical management and future perspectives
Tomasello, C., Baldessari, C., Napolitano, M., Orsi, G., Grizzi, G., Bertolini, F., Barbieri, F., & Cascinu, S. (2018) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2018.01.013 · Cited by 65
Resistance to molecularly targeted therapy in non-small-cell lung cancer
Asao, T., Takahashi, F., & Takahashi, K. (2018) · Respiratory Investigation · doi:10.1016/j.resinv.2018.09.001 · Cited by 62
Rebiopsy during disease progression in patients treated by TKI for oncogene-addicted NSCLC
Bosc, C., Ferretti, G., Cadranel, J. L., Audigier-Valette, C., Besse, B., Barlési, F., Decroisette, C., Lantuéjoul, S., Arbib, F., & Moro‐Sibilot, D. (2014) · Targeted Oncology · doi:10.1007/s11523-014-0332-y · Cited by 61
Epidermal Growth Factor Receptor (EGFR) Signaling and Covalent EGFR Inhibition in Lung Cancer
Heuckmann, J. M., Rauh, D., & Thomas, R. K. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2012.43.1825 · Cited by 61
IL-8 signaling is involved in resistance of lung carcinoma cells to erlotinib
Fernando, R. I., Hamilton, D. H., Dominguez, C. L., David, J. M., McCampbell, K. K., & Palena, C. (2016) · Oncotarget · doi:10.18632/oncotarget.9662 · Cited by 62
Targeting the hepatocyte growth factor/Met pathway in cancer
Silva, D. M. D., Roy, A., Kato, T., Cecchi, F., Lee, Y. H., Matsumoto, K., & Bottaro, D. P. (2017) · Biochemical Society Transactions · doi:10.1042/bst20160132 · Cited by 61
Acquired Resistance of EGFR-Mutated Lung Cancer to Tyrosine Kinase Inhibitor Treatment Promotes PARP Inhibitor Sensitivity
Marcar, L., Bardhan, K., Gheorghiu, L., Dinkelborg, P. H., Pfäffle, H. N., Liu, Q., Wang, M., Piotrowska, Z., Sequist, L. V. D., Borgmann, K., et al. (2019) · Cell Reports · doi:10.1016/j.celrep.2019.05.058 · Cited by 63
Self-citation
The role of HGF/c-MET signaling pathway in lymphoma
Lam, B., Dai, L., & Qin, Z. (2016) · Journal of Hematology & Oncology · doi:10.1186/s13045-016-0366-y · Cited by 60
Tivantinib (ARQ 197) efficacy is independent of MET inhibition in non‐small‐cell lung cancer cell lines
Calles, A., Kwiatkowski, N. P., Cammarata, B. K., Ercan, D., Gray, N. S., & Janne, P. A. (2014) · Molecular Oncology · doi:10.1016/j.molonc.2014.08.011 · Cited by 58
Nanomedicine Strategies for Management of Drug Resistance in Lung Cancer
Haider, M. A., Elsherbeny, A., Pittalà, V., Fallica, A. N., Alghamdi, M. A., Hussain, Z., Khoder, G., & Greish, K. F. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23031853 · Cited by 62
Rethinking cancer targeting strategies in the era of smart cell therapeutics
Allen, G. M., & Lim, W. A. (2022) · Nature reviews. Cancer · doi:10.1038/s41568-022-00505-x · Cited by 61
Dramatic Antitumor Effects of the Dual MET/RON Small-Molecule Inhibitor LY2801653 in Non–Small Cell Lung Cancer
Kawada, I., Hasina, R., Arif, Q., Mueller, J. S., Smithberger, E., Husain, A. N., Vokes, E. E., & Salgia, R. (2013) · Cancer Research · doi:10.1158/0008-5472.can-12-3583 · Cited by 59
Acquired Resistance to Dasatinib in Lung Cancer Cell Lines Conferred by DDR2 Gatekeeper Mutation and NF1 Loss
Beauchamp, E. M., Woods, B. A., Dulak, A. M., Tan, L., Xu, C., Gray, N. S., Bass, A. J., Wong, K., Meyerson, M. M., & Hammerman, P. S. (2013) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-13-0817 · Cited by 60
PDGFR-modulated miR-23b cluster and miR-125a-5p suppress lung tumorigenesis by targeting multiple components of KRAS and NF-kB pathways
Naidu, S., Shi, L., Magee, P., Middleton, J. D., Laganà, A., Sahoo, S., Leong, H. S., Galvin, M., Frese, K. K., Dive, C., et al. (2017) · Scientific Reports · doi:10.1038/s41598-017-14843-6 · Cited by 59
Enhanced YAP expression leads to EGFR TKI resistance in lung adenocarcinomas
Lee, T., Tseng, Y.-C., Nguyễn, P. A., Li, Y., Ho, C., & Wu, C.-W. (2018) · Scientific Reports · doi:10.1038/s41598-017-18527-z · Cited by 60
Enapotamab vedotin, an AXL-specific antibody-drug conjugate, shows preclinical antitumor activity in non-small cell lung cancer
Koopman, L. A., Terp, M. G., Zom, G. G., Janmaat, M. L., Jacobsen, K., den Heuvel, E. G.-V., Brandhorst, M., Forssmann, U., Bree, F. D., Pencheva, N., et al. (2019) · JCI Insight · doi:10.1172/jci.insight.128199 · Cited by 59
Overcoming resistance to targeted therapies in NSCLC: current approaches and clinical application
Maione, P., Sacco, P. C., Sgambato, A., Casaluce, F., Rossi, A., & Gridelli, C. (2015) · Therapeutic Advances in Medical Oncology · doi:10.1177/1758834015595048 · Cited by 59
SPSB1 Promotes Breast Cancer Recurrence by Potentiating c-MET Signaling
Feng, Y., Pan, T.-C., Pant, D. K., Chakrabarti, K. R., Alvarez, J. V., Ruth, J. R., & Chodosh, L. A. (2014) · Cancer Discovery · doi:10.1158/2159-8290.cd-13-0548 · Cited by 58
Multimodal single-cell and whole-genome sequencing of small, frozen clinical specimens
Wang, Y., Fan, J. L., Melms, J. C., Amin, A. D., Georgis, Y., Barrera, I., Ho, P., Tagore, S., Abril-Rodríguez, G., He, S., et al. (2023) · Nature Genetics · doi:10.1038/s41588-022-01268-9 · Cited by 59
Identification of PLX 4032‐resistance mechanisms and implications for novel RAF inhibitors
Choi, J., Landrette, S. F., Wang, T. L., Evans, P., Bacchiocchi, A., Bjornson, R. D., Cheng, E., Stiegler, A. L., Gathiaka, S. M., Acevedo, O., et al. (2013) · Pigment Cell & Melanoma Research · doi:10.1111/pcmr.12197 · Cited by 58
Conversion from the “oncogene addiction” to “drug addiction” by intensive inhibition of the EGFR and MET in lung cancer with activating EGFR mutation
Suda, K., Tomizawa, K., Osada, H., Maehara, Y., Yatabe, Y., Sekido, Y., & Mitsudomi, T. (2011) · Lung Cancer · doi:10.1016/j.lungcan.2011.11.007 · Cited by 56
Bufalin Reverses HGF-Induced Resistance to EGFR-TKIs in EGFR Mutant Lung Cancer Cells via Blockage of Met/PI3k/Akt Pathway and Induction of Apoptosis
Kang, X.-H., Xu, Z.-Y., Gong, Y.-B., Wang, L., Wang, Z., Xu, L., Cao, F., & Liao, M.-J. (2013) · Evidence-based Complementary and Alternative Medicine · doi:10.1155/2013/243859 · Cited by 58
c-Myc Alterations Confer Therapeutic Response and Acquired Resistance to c-Met Inhibitors in MET-Addicted Cancers
Shen, A., Wang, L., Huang, M., Sun, J., Chen, Y., Shen, Y., Yang, X., Wang, X., Ding, J., & Geng, M. (2015) · Cancer Research · doi:10.1158/0008-5472.can-14-2743 · Cited by 59
Analysis ofEGFR,EML4-ALK,KRAS, andc-METmutations in Chinese lung adenocarcinoma patients
Xia, N., An, J., Jiang, Q., Li, M., Tan, J., & Hu, C. (2013) · Experimental Lung Research · doi:10.3109/01902148.2013.819535 · Cited by 57
Combined Pan-HER and ALK/ROS1/MET Inhibition with Dacomitinib and Crizotinib in Advanced Non–Small Cell Lung Cancer: Results of a Phase I Study
Janne, P. A., Shaw, A. T., Camidge, D. R., Giaccone, G., Shreeve, S. M., Tang, Y., Goldberg, Z., Martini, J., Xu, H., James, L. P., et al. (2016) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2016.01.022 · Cited by 57
The Clonal Evolution of Metastatic Osteosarcoma as Shaped by Cisplatin Treatment
Brady, S. W., Ma, X., Bahrami, A., Satas, G., Wu, G., Newman, S., Rusch, M., Putnam, D. K., Mulder, H. L., Yergeau, D. A., et al. (2019) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-18-0620 · Cited by 52
CuS Nanoparticles as a Photodynamic Nanoswitch for Abrogating Bypass Signaling To Overcome Gefitinib Resistance
Gu, X., Qiu, Y., Lin, M., Cui, K., Chen, G., Chen, Y., Fan, C., Zhang, Y., Xu, L., Chen, H., et al. (2019) · Nano Letters · doi:10.1021/acs.nanolett.9b01065 · Cited by 58
MET Gene Copy Number Predicts Worse Overall Survival in Patients with Non-Small Cell Lung Cancer (NSCLC); A Systematic Review and Meta-Analysis
Dimou, A., Non, L. R., Chae, Y. K., Tester, W. J., & Syrigos, K. N. (2014) · PLoS ONE · doi:10.1371/journal.pone.0107677 · Cited by 56
Impact of Genomics on Personalized Cancer Medicine
Arteaga, C. L., & Baselga, J. M. (2012) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-2019 · Cited by 57
In Vitro and In Vivo Activity of AMG 337, a Potent and Selective MET Kinase Inhibitor, in MET-Dependent Cancer Models
Hughes, P. E., Rex, K. L., Caenepeel, S. R., Yang, Y., Zhang, Y., Broome, M. A., Kha, H. T., Burgess, T. L., Amore, B. M., Kaplan‐Lefko, P. J., et al. (2016) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-15-0871 · Cited by 56
Cancer therapy: an evolved approach
Willyard, C. (2016) · Nature · doi:10.1038/532166a · Cited by 57
MET amplification identified by next-generation sequencing and its clinical relevance for MET inhibitors
Peng, L.-X., Jie, G., Li, A., Liu, S. M., Sun, H., Zheng, M.-M., Zhou, J., Zhang, J., Zhang, X., Zhou, Q. H., et al. (2021) · Experimental Hematology and Oncology · doi:10.1186/s40164-021-00245-y · Cited by 55
Self-citation
INSIGHT 2: a Phase II Study of Tepotinib Plus Osimertinib in MET -Amplified NSCLC and First-Line Osimertinib Resistance
Smit, E. F., Dooms, C., Raskin, J., Nadal, E., Tho, L. M., Le, X., Mazières, J., Hin, H. S., Morise, M., Zhu, V. W., et al. (2021) · Future Oncology · doi:10.2217/fon-2021-1406 · Cited by 56
Self-citation
Molecular pathways, resistance mechanisms and targeted interventions in non-small-cell lung cancer
Wang, Z., Xing, Y., Li, B., Li, X., Liu, B., & Wang, Y. (2022) · Molecular Biomedicine · doi:10.1186/s43556-022-00107-x · Cited by 62
Inhibition of Casein Kinase 1 Alpha Prevents Acquired Drug Resistance to Erlotinib in EGFR-Mutant Non–Small Cell Lung Cancer
Lantermann, A. B., Chen, D., McCutcheon, K., Hoffman, G., Frias, E., Ruddy, D. A., Rakiec, D. P., Korn, J. M., McAllister, G., Stegmeier, F. P., et al. (2015) · Cancer Research · doi:10.1158/0008-5472.can-15-1113 · Cited by 56
Mechanisms of Resistance to EGFR Tyrosine Kinase Inhibitors and Therapeutic Approaches: An Update
Ahsan, A. (2015) · Advances in experimental medicine and biology · doi:10.1007/978-3-319-24223-1_7 · Cited by 56
Translating neoadjuvant therapy into survival benefits: one size does not fit all
Mattos‐Arruda, L. D., Shen, R., Reis-Filho, J. S., & Cortés, J. (2016) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2016.35 · Cited by 52
Re-Evaluating Clonal Dominance in Cancer Evolution
Burrell, R. A., & Swanton, C. (2016) · Trends in cancer · doi:10.1016/j.trecan.2016.04.002 · Cited by 54
Cisplatin influences acquisition of resistance to molecular‐targeted agents through epithelial–mesenchymal transition‐like changes
Kurokawa, M., Ise, N., Omi, K., Goishi, K., & Higashiyama, S. (2013) · Cancer Science · doi:10.1111/cas.12171 · Cited by 52
Four individually druggable MET hotspots mediate HGF-driven tumor progression
Basilico, C., Hultberg, A., Blanchetot, C., Jonge, N. D., Festjens, E., Hanssens, V., Osepa, S.-I., Boeck, G. D., Mira, A., Cazzanti, M., et al. (2014) · Journal of Clinical Investigation · doi:10.1172/jci72316 · Cited by 54
Diagnostic significance of cerebrospinal fluid EGFR mutation analysis for leptomeningeal metastasis in non-small-cell lung cancer patients harboring an active EGFR mutation following gefitinib therapy failure
Sasaki, S., Yoshioka, Y., Ko, R., Katsura, Y., Namba, Y., Shukuya, T., Kido, K., Iwakami, S., Tominaga, S., & Takahashi, K. (2015) · Respiratory Investigation · doi:10.1016/j.resinv.2015.07.001 · Cited by 53
Butein, a novel dual inhibitor of MET and EGFR, overcomes gefitinib‐resistant lung cancer growth
Jung, S. K., Lee, M., Lim, D. Y., Lee, S., Jeong, C., Kim, J., Lim, T. G., Chen, H., Bode, A. M., Lee, H. J., et al. (2014) · Molecular Carcinogenesis · doi:10.1002/mc.22191 · Cited by 53
Overcoming erlotinib resistance with tailored treatment regimen in patient‐derived xenografts from naïve Asian NSCLC patients
Yang, M., Shan, B., Li, Q., Song, X., Cai, J., Deng, J., Zhang, L., 杜镇建, Lu, J., Chen, T., et al. (2012) · International Journal of Cancer · doi:10.1002/ijc.27813 · Cited by 53
Mechanisms of intrinsic and acquired resistance to kinase‐targeted therapies
Bagrodia, S., Smeal, T., & Abraham, R. T. (2012) · Pigment Cell & Melanoma Research · doi:10.1111/pcmr.12007 · Cited by 56
Absolute Quantitation of Met Using Mass Spectrometry for Clinical Application: Assay Precision, Stability, and Correlation with MET Gene Amplification in FFPE Tumor Tissue
Catenacci, D. V. T., Liao, W., Thyparambil, S. P., Henderson, L., Xu, P., Zhao, L., Rambo, B., Hart, J. A. L., Xiao, S., Bengali, K. M., et al. (2014) · PLoS ONE · doi:10.1371/journal.pone.0100586 · Cited by 53
Clinical approaches to treat patients with non-small cell lung cancer and epidermal growth factor receptor tyrosine kinase inhibitor acquired resistance
Tartarone, A., & Lerose, R. (2015) · Therapeutic Advances in Respiratory Disease · doi:10.1177/1753465815587820 · Cited by 54
Quantitative Tyrosine Phosphoproteomics of Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitor-treated Lung Adenocarcinoma Cells Reveals Potential Novel Biomarkers of Therapeutic Response
Zhang, X., Maity, T. K., Kashyap, M. K., Bansal, M., Venugopalan, A. K., Singh, S., Awasthi, S., Marimuthu, A., Jacob, H. K. C., Belkina, N., et al. (2017) · Molecular & Cellular Proteomics · doi:10.1074/mcp.m117.067439 · Cited by 50
Identification of genetic alterations associated with primary resistance to EGFR‐TKIs in advanced non‐small‐cell lung cancer patients with EGFR sensitive mutations
Wang, F., Diao, X., Zhang, X., Shao, Q., Feng, Y., An, X., & Wang, H. (2019) · 癌症：英文版 · doi:10.1186/s40880-019-0354-z · Cited by 54
Breast cancer genome heterogeneity: a challenge to personalised medicine?
Swanton, C., Burrell, R. A., & Futreal, P. A. (2011) · Breast Cancer Research · doi:10.1186/bcr2807 · Cited by 53
Impaired c-Met Receptor Degradation Mediated by MET Exon 14 Mutations in Non–Small-Cell Lung Cancer
Awad, M. M. (2016) · Journal of Clinical Oncology · doi:10.1200/jco.2015.64.2777 · Cited by 56
Recent updates on the resistance mechanisms to epidermal growth factor receptor tyrosine kinase inhibitors and resistance reversion strategies in lung cancer
Tripathi, S. K., Pandey, K., Rengasamy, K. R. R., & Biswal, B. K. (2020) · Medicinal Research Reviews · doi:10.1002/med.21700 · Cited by 54
Preclinical Study of a Biparatopic METxMET Antibody–Drug Conjugate, REGN5093-M114, Overcomes MET-driven Acquired Resistance to EGFR TKIs in EGFR-mutant NSCLC
Oh, S. Y., Lee, Y. W., Lee, E. J., Kim, J. H., Park, Y., Heo, S. G., Yu, M. R., Hong, M. H., DaSilva, J. O., Daly, C., et al. (2022) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-22-2180 · Cited by 51
Impact of Intertumoral Heterogeneity on Predicting Chemotherapy Response of BRCA1-Deficient Mammary Tumors
Rottenberg, S., Vollebergh, M. A., de Hoon, B., de Ronde, J., Schouten, P. C., Kersbergen, A. J., Zander, S. A. L., Pajic, M., Jaspers, J. E., Jonkers, M., et al. (2012) · Cancer Research · doi:10.1158/0008-5472.can-11-4201 · Cited by 52
Targeting the MET oncogene in cancer and metastases
Stella, G. M., Benvenuti, S., & Comoglio, P. M. (2010) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.2010.522988 · Cited by 52
Chemical Proteomics Uncovers EPHA2 as a Mechanism of Acquired Resistance to Small Molecule EGFR Kinase Inhibition
Koch, H., Busto, M. E. D. C., Kramer, K., Médard, G., & Küster, B. (2015) · Journal of Proteome Research · doi:10.1021/acs.jproteome.5b00161 · Cited by 51
Inferring mutational timing and reconstructing tumour evolutionary histories
Turajlic, S., McGranahan, N., & Swanton, C. (2015) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2015.03.005 · Cited by 53
Prognostic and predictive value of MET deregulation in non-small cell lung cancer.
Finocchiaro, G., Toschi, L., Gianoncelli, L., Baretti, M., & Santoro, A. (2015) · PubMed Central · doi:10.3978/j.issn.2305-5839.2015.03.43 · Cited by 57
Self-citation
Adaptation and selection shape clonal evolution of tumors during residual disease and recurrence
Walens, A., Lin, J., Damrauer, J. S., McKinney, B. J., Lupo, R., Newcomb, R., Fox, D. B., Mabe, N. W., Gresham, J. S., Sheng, Z., et al. (2020) · Nature Communications · doi:10.1038/s41467-020-18730-z · Cited by 52
Resistance to receptor tyrosine kinase inhibition in cancer: molecular mechanisms and therapeutic strategies
Alexander, P. B., & Wang, X. (2015) · Frontiers of Medicine · doi:10.1007/s11684-015-0396-9 · Cited by 50

Authors: Turke, A. B., Zejnullahu, K., Wu, Y.-L., Song, Y., Dias-Santagata, D., Lifshits, E., Toschi, L., Rogers, A., Mok, T., Sequist, L., Lindeman, N. I., Murphy, C., Akhavanfard, S., Yeap, B. Y., Xiao, Y., Capelletti, M., Iafrate, A. J., Lee, C., Christensen, J. G., Engelman, J. A., & Jänne, P. A.
Affiliations: Harvard University (US)
Dana-Farber Cancer Institute (US)
Guangdong General Hospital (CN)
Massachusetts General Hospital (US)
Chinese University of Hong Kong (HK)
Brigham and Women's Hospital (US)
Pfizer (United States) (US)
Corresponding author: Engelman, Jeffrey A.
ORCID: Wu, Yi-Long
Song, Youngchul
Dias-Santagata, Dora
Toschi, Luca
Mok, Tony
Sequist, Lecia
Lindeman, Neal I.
Akhavanfard, Sara
Yeap, Beow Y.
Capelletti, Marzia
Iafrate, A. John
Lee, Charles
Christensen, James G.
Engelman, Jeffrey A.
Venue: Cancer Cell
Publisher: Elsevier BV
Published: 2010-01
Volume: 17
Issue: 1
Pages: 77-88
ISSN: 1535-6108 (ISSN-L)
DOI: 10.1016/j.ccr.2009.11.022
PMC: PMC2980857
OpenAlex: W1985264867
Cited by: 1,059
References: 37
Citations by year: 2026: 22 · 2025: 31 · 2024: 36 · 2023: 58 · 2022: 41 · 2021: 55 · 2020: 41 · 2019: 56 · 2018: 66 · 2017: 73 · 2016: 93 · 2015: 84 · 2014: 88 · 2013: 94 · 2012: 106
FWCI: 83.75
Type: journal article
Language: en
Open access: bronze
doi.org
Licence: www.elsevier.com/tdm/userlicense/1.0/ (tdm)
www.elsevier.com/open-access/userlicense/1.0/ (vor, 1293 d)
Locations: Cancer Cell (publishedVersion)
PubMed (publishedVersion)
Europe PMC (PubMed Central) (acceptedVersion)
PubMed Central (acceptedVersion)
Funders: Guangdong Provincial Hospital of Traditional Chinese Medicine
University of Hong Kong
Chinese University of Hong Kong
National Institutes of Health
National Cancer Institute (P50CA127003, R01CA140594, R01CA114465, P50CA090578, R01CA135257, K08CA120060, R01CA137008)
Topics: Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Treatments and Mutations
Health Sciences › Medicine › Oncology › HER2/EGFR in Cancer Research
Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer Genomics and Diagnostics
Keywords: MET amplification, EGFR mutation, non-small cell lung cancer, hepatocyte growth factor, clonal selection, combination therapy
MeSH terms: Animals, Antineoplastic Agents, Carcinoma, Non-Small-Cell Lung, Gene Amplification, Humans, Lung Neoplasms, Mutation, Proto-Oncogene Proteins, Signal Transduction, Gene Expression, Polymerase Chain Reaction, Hepatocyte Growth Factor, In Situ Hybridization, Fluorescence, Receptors, Growth Factor, Drug Resistance, Neoplasm, Proto-Oncogene Proteins c-met, Xenograft Model Antitumor Assays, Cell Line, Tumor, Mice, Quinazolinones, ErbB Receptors

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Preexistence and Clonal Selection of MET Amplification in EGFR Mutant NSCLC

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks